

# Trends and Economic Impact of Medication Errors in Public Hospitals of Eastern Region, Ghana: A Retrospective Analysis from 2018 to 2024

HSD117

Archibald Okotah<sup>1,3</sup>, Leslie Vanderpuije<sup>1</sup>, Josephine Osarfo<sup>1</sup>, Isaac Kwaku Obiri – Yeboa<sup>2</sup>, Winfred Ofosu<sup>2</sup>, Nii Obodai Mensah<sup>2</sup>

1. AJ Health and Research Consult, #3 Asafoatse baakunkor st, Accra, Ghana.

2. Eastern Regional Health Directorate, Ghana Health Service, Ghana

3. Britts Pharma Limited, Accra - Ghana

## Introduction

Medication errors (ME) are a serious threat to patient safety and healthcare system efficiency, particularly in resource-limited settings like Ghana. Despite growing efforts to improve care quality, the financial and clinical impacts of these errors remain under documented, due to limited reporting and inadequate data on health economics research in Ghana

## Results

**Demographics:** The mean patient age was 40.7 years ( $\pm 24.1$  SD), with females accounting for 68% of all intervention forms accessed.

**ME identification:** Most errors were identified by Pharmacists (65.4%) and originated during the ordering/prescribing stage (90.5%).

**ME type:** The most prevalent error type was wrong dosage (57.3%), followed by wrong drug (18.4%) and wrong drug combinations (7.4%). Other types of errors include contraindication, omission error and wrong dosage form

**ME Cost analysis:** The total pre-intervention cost of error was GH¢1,091,954 (\$103,907), while post-intervention costs amounted to GH¢340,351 (\$34,200), resulting in GH¢751,578 (\$69,707) in savings - a 68.8% reduction. Cost savings varied annually, with the highest annual cost saving recorded in 2024 (GH¢503,906; 81.8%). Age was a significant predictor of cost of error, with older age (particularly 65 years+) resulting in the highest cost of error compared with other age categories ( $\beta = GH¢115.4; p < 0.001, 95\% CI: 62.29-168.59$ ).

## Objectives

This study seeks to quantify the cost trends from medication error interventions and to identify the demographic and clinical factors associated with error related costs in public hospitals in Ghana's Eastern Region.

## Methods

A retrospective, cross-sectional analysis was conducted using a standardized medication error intervention forms submitted by 24 public hospitals (across 19 districts) in Ghana's Eastern Region from 2018 to 2024. The 2021 data was excluded from analysis due to incomplete records. 10,283 medication error intervention forms were reviewed for patient demographics, error type and stage, personnel involved, medication characteristics, and corrective actions. Cost estimations were performed from the health system payer perspective using the National Health Insurance Scheme (NHIS) pricing framework, comparing medication costs before and after interventions to quantify potential savings. Data were analyzed in STATA version 15, with continuous variables summarized as mean  $\pm$  SD and categorical variables as frequencies and percentages. Multiple linear regression model assessed factors influencing cost variations, using pre-intervention medication cost as dependent variable and patient age, gender, error type, error stage, personnel category, and number of diagnosis as independent variables. Statistical significance was set at  $p < 0.05$ . Ethical approval and administrative clearance were obtained from the Eastern Regional Health Directorate (ERHD), and confidentiality of patient data was strictly maintained throughout the study.

Table 1 : ME originating stage (Location), N (%), N = Number of error intervention forms

| Year         | Ordering / prescribing | Transcribing     | Dispensing         | Administration    | Total             |
|--------------|------------------------|------------------|--------------------|-------------------|-------------------|
| 2018         | 534 (96.22%)           | 6 (1.08%)        | 13 (2.34%)         | 2 (0.36%)         | 555(5.42)         |
| 2019         | 799 (97.92%)           | 0 (0.00%)        | 16 (1.96%)         | 1 (0.12%)         | 816(7.96)         |
| 2020         | 641 (94.40%)           | 0 (0.00%)        | 36 (5.30%)         | 2 (0.29%)         | 679(6.63)         |
| 2022         | 1,067 (92.62%)         | 0 (0.00%)        | 81 (7.03%)         | 4 (0.35%)         | 1,152(11.24)      |
| 2023         | 3,067 (86.52%)         | 0 (0.00%)        | 465 (13.12%)       | 13 (0.37%)        | 3545(34.59)       |
| 2024         | 3,163 (90.32%)         | 0 (0.00%)        | 338 (9.65%)        | 1 (0.03%)         | 3502(34.17)       |
| <b>Total</b> | <b>9,271 (90.46%)</b>  | <b>6 (0.06%)</b> | <b>949 (9.26%)</b> | <b>23 (0.22%)</b> | <b>10249(100)</b> |

Table 2: Trend of Medication error costs

| Year               | Cost Before Intervention<br>GHS (USD) | Cost After Intervention<br>GHS (USD) | Cost Saved<br>GHS (USD) | % Cost Saved |
|--------------------|---------------------------------------|--------------------------------------|-------------------------|--------------|
| 2018               | 29,546 (6,117)                        | 6,099 (1,263)                        | 23,447 (4,854)          | 79.36        |
| 2019               | 55,315 (9,721)                        | 28,940 (5,086)                       | 26,375 (4,635)          | 47.68        |
| 2020               | 147,636 (25,237)                      | 42,464 (7,259)                       | 105,172 (17,978)        | 71.24        |
| 2022               | 33,826 (3,349)                        | 22,013 (2,180)                       | 11,812 (1,170)          | 34.92        |
| 2023               | 210,102 (17,582)                      | 129,212 (10,813)                     | 80,865 (6,767)          | 38.49        |
| 2024               | 615,529 (41,901)                      | 111,623 (7,599)                      | 503,906 (34,303)        | 81.87        |
| <b>Grand Total</b> | <b>1,091,954 (103,907)</b>            | <b>340,351 (34,200)</b>              | <b>751,578 (69,707)</b> | <b>68.83</b> |

Table 3 : Error Type / classification

| YR           | Wrong dosage(N, %) | Wrong dosage form(N, %) | Wrong drug(N, %)   | Omission error(N, %) | Contraindications(N, %) | Wrong drug combination s(N, %) | Wrong route administration (N, %) | Other error category(N, %) | Total(N, %)          |
|--------------|--------------------|-------------------------|--------------------|----------------------|-------------------------|--------------------------------|-----------------------------------|----------------------------|----------------------|
| 2018         | 404(72.40)         | 84(15.05)               | 5(0.90)            | 17(3.05)             | 22(3.94)                | 21(3.76)                       | 1(0.18)                           | 4(0.72)                    | 558(5.47)            |
| 2019         | 537(64.54)         | 5(0.60)                 | 90(10.82)          | 32(3.85)             | 42(5.05)                | 76(9.13)                       | 0(0.00)                           | 50(6.01)                   | 832(8.16)            |
| 2020         | 427(61.88)         | 14(2.03)                | 108(15.65)         | 24(3.48)             | 26(3.77)                | 77(11.16)                      | 0(0.00)                           | 14(2.03)                   | 690(6.77)            |
| 2022         | 616(53.47)         | 30(2.60)                | 162(14.06)         | 119(10.33)           | 65(5.64)                | 152(13.19)                     | 0(0.00)                           | 8(0.69)                    | 1152(11.30)          |
| 2023         | 1811(52.20)        | 32(0.92)                | 731(21.07)         | 150(4.32)            | 217(6.26)               | 177(5.10)                      | 0(0.00)                           | 351(10.12)                 | 3469(34.03)          |
| 2024         | 2042(58.48)        | 77(2.21)                | 774(22.16)         | 111(3.18)            | 168(4.81)               | 253(7.25)                      | 13(0.37)                          | 54(1.55)                   | 3492(34.26)          |
| <b>Total</b> | <b>5837(57.26)</b> | <b>242(2.37)</b>        | <b>1870(18.35)</b> | <b>453(4.44)</b>     | <b>540(5.30)</b>        | <b>756(7.42)</b>               | <b>14(0.14)</b>                   | <b>481(4.72)</b>           | <b>10193(100.00)</b> |

## Conclusion

ME interventions substantially reduced the economic burden of medication errors, achieving a 68.8% cost reduction and GH¢ 751,578 (\$69,707) in cost savings across public hospitals in Ghana's Eastern Region. Older patients and specific error types were significantly associated with costs of error. Strengthening data-driven feedback systems and integrating pharmacist-led monitoring into routine practice are essential for sustaining cost savings and improving patient safety.

## Policy Implications

Integrating evidence-based medication safety and cost monitoring mechanisms into national health policy can translate observed savings into sustainable system-wide efficiency

CONTACT INFORMATION:  
Nii Obodai Mensah ([pesiobodai@Hotmail.com](mailto:pesiobodai@Hotmail.com)) +233 244 598 116 ;  
Archibald Okotah ([archibot4u@yahoo.co.uk](mailto:archibot4u@yahoo.co.uk)) +233 244 297 950

**ISPOR Europe 2025**  
9-12 November 2025 | Glasgow, Scotland, UK